Green Cross Corp
006280
Company Profile
Business description
Green Cross Corp is one of the global leaders in the healthcare sector. The Montreal-based biopharmaceutical company primarily develops intravenous immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and albumin, used as a blood-volumizing agent and in the treatment of burns. Currently, the company has a global presence through its association with various subsidiaries.
Contact
303 Bojeong-Dong
Giheung-Gu
YonginGyeonggi449-070
KORT: +82 312609300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
2,276
Stocks News & Analysis
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
stocks
Bookworm: Buy and hold inspiration from an unlikely source
Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.
stocks
3 ASX shares to avoid
These shares have surged in price in the last year but are significantly overvalued according to our analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,082.10 | 68.80 | 0.86% |
| CAC 40 | 8,029.51 | 1.23 | 0.02% |
| DAX 40 | 23,003.33 | 16.51 | 0.07% |
| Dow JONES (US) | 41,488.19 | 674.62 | 1.65% |
| FTSE 100 | 8,643.19 | 10.86 | 0.13% |
| HKSE | 24,145.57 | 185.59 | 0.77% |
| NASDAQ | 17,754.09 | 451.07 | 2.61% |
| Nikkei 225 | 37,396.52 | 343.42 | 0.93% |
| NZX 50 Index | 12,166.14 | 100.11 | -0.82% |
| S&P 500 | 5,638.94 | 117.42 | 2.13% |
| S&P/ASX 200 | 7,854.10 | 64.40 | 0.83% |
| SSE Composite Index | 3,426.13 | 6.57 | 0.19% |